^
    1d
    FIL_LymDeCo: Neurocognitive Assessment in Long-Term Survivors of Lymphoma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New trial
    1d
    A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> May 2026
    Enrollment closed • Trial primary completion date
    |
    Tazverik (tazemetostat)
    1d
    D7400C00006: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=226, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    surovatamig (AZD0486)
    1d
    Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma. (PubMed, Blood Adv)
    In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • FANCE (FA Complementation Group E)
    1d
    19-C-0116: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=132, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2030 --> Mar 2031 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    1d
    The CARDIOPROTECT Trial (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Beth Israel Deaconess Medical Center
    New P2 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • Truxima (rituximab-abbs) • Myocet (non-pegylated liposomal doxorubicin) • Polivy (polatuzumab vedotin-piiq) • dexrazoxane
    2d
    AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Mabtas (rituximab biosimilar)
    2d
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    2d
    Association between CD79B expression and polatuzumab vedotin efficacy, and therapy-induced changes in CD79B expression in diffuse large B-cell lymphoma. (PubMed, Virchows Arch)
    Among 24 patients with recurrent tumor biopsies, 13% showed loss of/decreased CD79B expression. In conclusion, immunohistochemical CD79B expression was not significantly associated with PV-containing therapy efficacy, which remained effective even in DLBCL with low CD79B expression.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD79B (CD79b Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive • CD20 negative
    |
    Polivy (polatuzumab vedotin-piiq)
    3d
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended
    Trial suspension
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)
    3d
    Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P2, N=11, Terminated, University of Washington | N=20 --> 11 | Trial completion date: Jul 2028 --> May 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2027 --> May 2026; The trial closed early due to slow accrual.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Zynlonta (loncastuximab tesirine-lpyl) • AMG 211
    3d
    Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report. (PubMed, Front Immunol)
    The patient was treated with Pola-R-CHP followed by CNS-directed therapy, including high-dose methotrexate and intrathecal chemotherapy...Tumor-associated RANKL expression may be associated with the osteolytic features observed in this case. Early biopsy and systemic evaluation of cutaneous lesions are essential, as they may reflect aggressive systemic disease.
    Journal
    |
    TNFSF11 (TNF Superfamily Member 11)
    |
    Polivy (polatuzumab vedotin-piiq) • methotrexate IV